【摘要】 目的:探究替罗非班治疗非大血管病变急性脑梗死(AIS)的临床疗效。方法:从江门市新会区人民医院收集2022年4月至2024年3月期间住院诊疗的60例非大血管病变AIS患者，随机划分为观察组(n=30)、参照组(n=30)。参照组施以常规治疗+AIS标准治疗，观察组基于参照组疗法加用替罗非班。持续治疗7～10天，比较两组治疗前后美国国立卫生院神经功能缺损评分量表(NIHSS)评分、日常生活功能量表(ADL)评分；比较两组临床疗效及用药安全性。结果:经治疗，两组ADL评分较治疗前升高，NIHSS评分较治疗前降低；观察组ADL评分与NIHSS评分改善较参照组优异(P<0.05)。与参照组有效率(80.00%)相比，观察组疗效有效率(96.67%)更高(P<0.05)。两组不良反应发生率比较，无统计学差异(P>0.05)。结论:临床采用替罗非班治疗非大血管病变AIS的效果明显，能有效促进神经功能恢复以及提升日常生活能力，且未增加不良反应发生风险，值得推广。更多还原

【Abstract】 Objective:To investigate the clinical efficacy of tirofiban in the treatment of non-macrovascular acute cerebral infarction(AIS). Methods:A total of 60 patients with AIS without macrovascular disease who were hospitalized from April 2022 to March 2024 in Xinhui District People’s Hospital of Jiangmen City were collected and randomly divided into observation group(n=30) and reference group(n=30). The reference group received conventional treatment plus AIS standard treatment, and the observation group received tirofiban based on the reference group therapy. After continuous treatment for 7～10 days, the National Institutes of Health Neurological Impairment Scale(NIHSS) score and ADL score were compared between the two groups before and after treatment. The clinical efficacy and drug safety of the two groups were compared. Results:After treatment, ADL score was higher than before treatment, NIHSS score was lower than before treatment. ADL score and NIHSS score in observation group improved better than that in reference group(P<0.05). The effective rate of the observation group(96.67%) was higher than that of the reference group(80.00%)(P<0.05). There was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion:The clinical application of tirofiban in the treatment of AIS with non-macrovascular disease is effective, which can effectively promote the recovery of neurological function and improve the ability of daily living without increasing the risk of adverse reactions.更多还原